{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:39:47Z","timestamp":1793965187877,"version":"4.8.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022776","name":"Stichting Haemophilia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022776","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.rpth.2024.102599","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T07:51:56Z","timestamp":1730274716000},"page":"102599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prophylaxis in von Willebrand disease with von Willebrand factor concentrate and nonfactor therapies"],"prefix":"10.1016","volume":"8","author":[{"given":"Calvin B.","family":"van Kwawegen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank W.G.","family":"Leebeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2024.102599_bib1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1055\/s-0037-1613992","article-title":"Impact, diagnosis and treatment of von Willebrand disease","volume":"84","author":"Sadler","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102599_bib2","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"Von Willebrand's disease","volume":"375","author":"Leebeek","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102599_bib3","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1160\/TH12-04-0244","article-title":"Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease","volume":"108","author":"de Wee","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102599_bib4","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1538-7836.2010.04175.x","article-title":"Impact of von Willebrand\u00a0disease on health-related quality of life in a pediatric population","volume":"9","author":"de Wee","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102599_bib5","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/j.1538-7836.2010.03864.x","article-title":"Health-related quality of life among adult patients with moderate and severe von Willebrand disease","volume":"8","author":"de Wee","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102599_bib6","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ajh.24195","article-title":"Bleeding spectrum in children with moderate or severe von Willebrand disease: relevance of pediatric-specific bleeding","volume":"90","author":"Sanders","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2024.102599_bib7","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1365-2516.2009.02025.x","article-title":"Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease","volume":"15","author":"Metjian","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102599_bib8","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1111\/hae.12670","article-title":"Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study","volume":"21","author":"van Galen","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102599_bib9","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3324\/haematol.2017.168617","article-title":"Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study","volume":"102","author":"van Galen","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2024.102599_bib10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12955-017-0643-7","article-title":"Predictors of quality of life among adolescents and young adults with a bleeding disorder","volume":"15","author":"McLaughlin","year":"2017","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.rpth.2024.102599_bib11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.thromres.2019.04.017","article-title":"Von Willebrand disease and gastrointestinal bleeding: a national inpatient sample study","volume":"178","author":"Tsagianni","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2024.102599_bib12","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/hae.12571","article-title":"The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease","volume":"21","author":"Makris","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102599_bib13","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood-2010-01-264507","article-title":"Endothelial von Willebrand factor regulates angiogenesis","volume":"117","author":"Starke","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102599_bib14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/jth.13551","article-title":"Von Willebrand factor and angiogenesis: basic and applied issues","volume":"15","author":"Randi","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102599_bib15","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/hematology.2022000390","article-title":"Special considerations in GI bleeding in VWD patients","volume":"2022","author":"Chornenki","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.rpth.2024.102599_bib16","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.3892\/etm.2016.3144","article-title":"Heavy menstrual bleeding and health-associated quality of life in women with von Willebrand's disease","volume":"11","author":"Govorov","year":"2016","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.rpth.2024.102599_bib17","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra040403","article-title":"Treatment of von Willebrand's disease","volume":"351","author":"Mannucci","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102599_bib18","first-page":"CD011385","article-title":"Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or von Willebrand disease undergoing minor oral surgery or dental extractions","volume":"12","author":"van Galen","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rpth.2024.102599_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1182\/bloodadvances.2021005589","article-title":"Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature","volume":"6","author":"Brignardello-Petersen","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102599_bib20","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/bmj.313.7057.579","article-title":"Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid","volume":"313","author":"Bonnar","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.rpth.2024.102599_bib21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/bloodadvances.2020003264","article-title":"ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease","volume":"5","author":"Connell","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102599_bib22","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/hae.12701","article-title":"Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature","volume":"21","author":"Engelen","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102599_bib23","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1365-2141.2008.07005.x","article-title":"Von Willebrand disease and angiodysplasia responding to atorvastatin","volume":"142","author":"Sohal","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2024.102599_bib24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2009.08031.x","article-title":"Von Willebrand disease, angiodysplasia and atorvastatin","volume":"149","author":"Alikhan","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2024.102599_bib25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/hae.12100","article-title":"History of prophylaxis","volume":"19","author":"Berntorp","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102599_bib26","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/01.mbc.0000167659.23262.18","article-title":"Long-term prophylaxis in von Willebrand disease","volume":"16","author":"Berntorp","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.rpth.2024.102599_bib27","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.thromres.2006.01.016","article-title":"The von Willebrand disease prophylaxis network (vWD PN): exploring a treatment concept","volume":"118","author":"Berntorp","year":"2006","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2024.102599_bib28","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/jth.12995","article-title":"Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network","volume":"13","author":"Abshire","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102599_bib29","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/MBC.0000000000000257","article-title":"Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network","volume":"26","author":"Holm","year":"2015","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.rpth.2024.102599_bib30","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jtha.2023.01.001","article-title":"von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS","volume":"21","author":"Pagliari","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102599_bib32","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1055\/s-0036-1581106","article-title":"Prophylaxis in von Willebrand disease: coming of age?","volume":"42","author":"Saccullo","year":"2016","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2024.102599_bib33","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/hae.14550","article-title":"Outcomes of long-term von Willebrand factor prophylaxis use in von Willebrand disease: a systematic literature review","volume":"28","author":"El Alayli","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102599_bib34","first-page":"391","article-title":"A\u00a0phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF\/FVIII concentrates in severe inherited von Willebrand disease","volume":"17","author":"Peyvandi","year":"2019","journal-title":"Blood Transfus"},{"key":"10.1016\/j.rpth.2024.102599_bib35","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/ejh.13778","article-title":"Effectiveness of long-term prophylaxis using pdFVIII\/VWF concentrate in patients with inherited von Willebrand disease","volume":"109","author":"Rugeri","year":"2022","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.rpth.2024.102599_bib36","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1182\/blood.2021014810","article-title":"Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results","volume":"140","author":"Leebeek","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102599_bib37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/ejh.13949","article-title":"Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: results of a post hoc analysis from a phase 3 trial","volume":"111","author":"Leebeek","year":"2023","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.rpth.2024.102599_bib38","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1160\/TH11-03-0180","article-title":"Gynaecological and obstetric bleeding in moderate and severe von Willebrand disease","volume":"106","author":"De Wee","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102599_bib39","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1046\/j.1365-2516.1998.00208.x","article-title":"Quality of life during menstruation in patients with inherited bleeding disorders","volume":"4","author":"Kadir","year":"1998","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102599_bib40","doi-asserted-by":"crossref","first-page":"e612","DOI":"10.1016\/S2352-3026(23)00119-9","article-title":"Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial","volume":"10","author":"Ragni","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2024.102599_bib41","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/hae.12005","article-title":"Efficacy and safety during formulation switch of a pasteurized VWF\/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease","volume":"19","author":"Castaman","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102599_bib42","doi-asserted-by":"crossref","first-page":"e561","DOI":"10.1016\/S2352-3026(23)00165-5","article-title":"Heavy menstrual blood loss in patients with von Willebrand disease: an unsolved problem","volume":"10","author":"Leebeek","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2024.102599_bib43","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/bloodadvances.2023011742","article-title":"von Willebrand factor\/factor VIII concentrate (Wilate) prophylaxis in children and adults with von Willebrand disease","volume":"8","author":"Sidonio","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102599_bib44","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1182\/blood-2023-180513","article-title":"Efficacy and safety of prophylaxis with a plasma-derived von Willebrand factor\/factor VIII concentrate in children and adolescents with von Willebrand disease - a sub-analysis of data from the Wil-31 study","volume":"142","author":"Sidonio","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102599_bib45","article-title":"Bleeding sites in von Willebrand disease patients on prophylaxis with a plasma-derived von Willebrand factor\/factor VIII concentrate \u2013 a sub-analysis of data from the WIL-31 study [abstract]","author":"Sidonio","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102599_bib46","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood.2024024209","article-title":"Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States","volume":"143","author":"Waldron","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102599_bib47","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-02-629873","article-title":"Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease","volume":"126","author":"Gill","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102599_bib48","first-page":"399","article-title":"Pharmacokinetic-pharmacodynamic comparison of recombinant and plasma-derived von Willebrand factor in patients with von Willebrand disease\u00a0type 3","volume":"14","author":"Bauer","year":"2023","journal-title":"J\u00a0Blood Med"},{"key":"10.1016\/j.rpth.2024.102599_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100545","article-title":"KB-V13A12, a novel nanobody-based therapeutic molecule for the treatment of von Willebrand disease [abstract]","volume":"7","author":"Peyron","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102599_bib50","first-page":"2891","article-title":"Efficacy of platelet-inspired hemostatic nanoparticles on bleeding in von Willebrand disease murine models","volume":"141","author":"Roullet","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102599_bib51","article-title":"Re-establishing von Willebrand factor production in endothelial cells derived from von Willebrand disease type 3 canine models through CRISPR-Cas9 mediated gene editing [abstract]","author":"Barraclough","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102599_bib52","article-title":"Allele specific knock-out of mutant von Willebrand factor in heterozygous Von Willebrand disease type 2A patient-derived ECFCs [abstract]","author":"B\u00e4r","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102599_bib53","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/bloodadvances.2020003891","article-title":"Population pharmacokinetics of the von Willebrand factor-factor VIII interaction in patients with von Willebrand disease","volume":"5","author":"Bukkems","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102599_bib54","article-title":"Personalized treatment by pharmacokinetic-guided dosing in von Willebrand disease; a prospective multicenter study, OPTI-CLOT\/To WiN study [abstract]","author":"Al Arashi","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102599_bib55","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/jth.14755","article-title":"The development and characterization of a long acting anti-thrombotic von Willebrand factor (VWF) aptamer","volume":"18","author":"Zhu","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102599_bib56","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1182\/bloodadvances.2022007805","article-title":"The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF\/FVIII in type 2B von Willebrand disease","volume":"6","author":"Ay","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102599_bib57","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1182\/blood.2024024055","article-title":"Aptamer BT200 blocks interaction of K1405-1408 in the VWF-A1 domain with macrophage LRP1","volume":"144","author":"Chion","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102599_bib58","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.3324\/haematol.2021.279948","article-title":"The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial","volume":"107","author":"Kovacevic","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2024.102599_bib59","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood.2022016571","article-title":"The von Willebrand factor-binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A","volume":"141","author":"Ay","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102599_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.101253","article-title":"Prophylactic efficacy of VGA039, an anti-protein s monoclonal antibody, in a novel non-human primate model of acquired von Willebrand disease [abstract]","volume":"7","author":"Huck","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102599_bib61","article-title":"VGA039, a protein S-targeting monoclonal antibody, demonstrates in a Phase Ia healthy volunteer trial the potential of subcutaneous weekly or less frequent prophylactic dosing for bleeding disorders [abstract]","author":"Schoergenhofer","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102599_bib62","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1182\/bloodadvances.2019000656","article-title":"Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies","volume":"3","author":"Weyand","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102599_bib63","article-title":"Emicizumab in type 3 von Willebrand disease: report of a case with an alloantibody and literature review","author":"Giuffrida","year":"2024","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2024.102599_bib64","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/MBC.0000000000001298","article-title":"Efficacy of emicizumab therapy in two adult patients with type 3 von Willebrand disease","volume":"35","author":"LeMaistre","year":"2024","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.rpth.2024.102599_bib65","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/jth.13938","article-title":"High and long-term von Willebrand factor expression after Sleeping Beauty transposon-mediated gene therapy in a mouse model of severe von Willebrand disease","volume":"16","author":"Portier","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102599_bib66","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/jth.14140","article-title":"Correction of a dominant-negative von Willebrand factor multimerization defect by small interfering RNA-mediated allele-specific inhibition of mutant von Willebrand factor","volume":"16","author":"de Jong","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102599_bib67","doi-asserted-by":"crossref","first-page":"6108","DOI":"10.1182\/bloodadvances.2023010643","article-title":"Small interfering RNA-mediated allele-selective silencing of von Willebrand factor in\u00a0vitro and in\u00a0vivo","volume":"7","author":"Jongejan","year":"2023","journal-title":"Blood Adv"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924002942?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924002942?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:34:45Z","timestamp":1738802085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037924002942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":66,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2475037924002942"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102599","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prophylaxis in von Willebrand disease with von Willebrand factor concentrate and nonfactor therapies","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102599","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102599"}}